Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging
- PMID: 17220728
- DOI: 10.1097/01.rli.0000251539.05400.06
Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging
Abstract
Objective: We sought to evaluate gadobenate dimeglumine for the detection and characterization of focal liver lesions in the unenhanced and already pre-enhanced liver.
Materials and methods: Sixty patients were evaluated prospectively. Unenhanced T1-weighted gradient echo (T1wGRE) and T2-weighted turbo spin echo (T2wTSE) images were acquired followed by contrast-enhanced T1wGRE images during the dynamic, equilibrium, and delayed phases after the bolus injection of 0.05 mmol/kg gadobenate dimeglumine. An identical series of dynamic images was then acquired after the delayed scan following a second 0.05 mmol/kg bolus of gadobenate dimeglumine. Images were evaluated randomly in 2 sessions by 3 independent blinded readers. Evaluated images in the first session comprised the unenhanced images, the first or second set of dynamic images, and the delayed images. The second session included the unenhanced images, the dynamic images not yet evaluated in the first session, and the delayed images. The 2 reading sessions were compared for lesion characterization and diagnosis, and kappa (kappa) values for interobserver agreement were determined. Quantitative evaluation of lesion contrast enhancement was also performed.
Results: The enhancement behavior in the second dynamic series was similar to that in the first series, although pre-enhancement of the normal liver resulted in reduced lesion-liver contrast-to-noise ratios and the visualization of some lesions only on arterial phase images. Typical imaging features for the lesions included in the study were visualized clearly in both series. Strong agreement (kappa=0.56-0.89; all evaluations) between the 2 images sets was noted by all readers for differentiation of benign from malignant lesions and for definition of specific diagnosis, and between readers for diagnoses established based on images acquired in the unenhanced and pre-enhanced liver.
Conclusion: Dynamic imaging in the hepatobiliary phase gives similar information as dynamic imaging of the unenhanced liver. This might prove advantageous for screening protocols involving same session imaging of primary extrahepatic tumors and liver.
Similar articles
-
Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose.Eur J Radiol. 2008 Apr;66(1):65-74. doi: 10.1016/j.ejrad.2007.04.022. Epub 2007 Jun 6. Eur J Radiol. 2008. PMID: 17555901 Clinical Trial.
-
Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine.Invest Radiol. 2009 Feb;44(2):95-104. doi: 10.1097/RLI.0b013e3181911eab. Invest Radiol. 2009. PMID: 19077911 Clinical Trial.
-
[Evaluation of Gd-BOPTA and Gd-DTPA in contrast-enhanced MR imaging of the liver].Zhonghua Zhong Liu Za Zhi. 2006 Feb;28(2):111-5. Zhonghua Zhong Liu Za Zhi. 2006. PMID: 16750014 Clinical Trial. Chinese.
-
Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg).Magn Reson Imaging Clin N Am. 1996 Feb;4(1):61-72. Magn Reson Imaging Clin N Am. 1996. PMID: 8673717 Review.
-
MultiHance: help or hype?J Comput Assist Tomogr. 1999 Nov;23 Suppl 1:S151-9. J Comput Assist Tomogr. 1999. PMID: 10608411 Review.
Cited by
-
Facile preparation of a new gadofullerene-based magnetic resonance imaging contrast agent with high 1H relaxivity.Bioconjug Chem. 2009 Jun;20(6):1186-93. doi: 10.1021/bc900051d. Bioconjug Chem. 2009. PMID: 19445504 Free PMC article.
-
Misleading findings of liver-specific MR contrast agent for radiological diagnosis of cysto-biliary communication in hydatid cysts.Radiol Med. 2019 Jun;124(6):460-466. doi: 10.1007/s11547-019-01000-4. Epub 2019 Feb 6. Radiol Med. 2019. PMID: 30725396
-
The value of gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase for predicting post-hepatectomy liver failure in HCC patients.Eur Radiol. 2022 Dec;32(12):8608-8616. doi: 10.1007/s00330-022-08874-5. Epub 2022 May 31. Eur Radiol. 2022. PMID: 35639146
-
Detection of liver metastases on gadobenate dimeglumine-enhanced MRI: systematic review, meta-analysis, and similarities with gadoxetate-enhanced MRI.Eur Radiol. 2019 Oct;29(10):5205-5216. doi: 10.1007/s00330-019-06110-1. Epub 2019 Mar 26. Eur Radiol. 2019. PMID: 30915560
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical